edwards life sciences products according to the list
edwards lifesciences (israel) ltd - רופא
cardiac output monitor and volume view set
a.m.i. technologies, ltd. - רופא - montage dual filter system
haemofiltration machine + accessories
"אי סי טי מדיקל בע""מ " - רופא - מכשיר להמופילטרציה + אביזרים
cardiac output monitor and volume view set
לבנט טכנולוגיות בע"מ - רופא
biological thv sapians valves rings
לבנט טכנולוגיות בע"מ - מומחה - השתלה / החלפה של מסתמים ביולוגיים וטבעות לחולים עם מחלת לב מסתמית.
pressure monitoring kit
ביומטריקס - רופא - tpd מערכת לשימוש חד פעמי למדידת לחצים עורקייים או ורידיים הכוללת צנרת קשיחה
לוסנטיס
novartis israel ltd - ranibizumab - תמיסה להזרקה - ranibizumab 10 mg/ml - ranibizumab - ranibizumab - treatment of patients with neovascular (wet) age-related macular degeneration (amd).treatment of adult patients with visual impairment due to diabetic macular oedema (dme) .the treatment of visual impairement due to macular oedema secondary to retinal vein occulsion (rvo).the treatment of visual impaiment due to choroidal neovacularization (cnv) secondary to pathologic myopia (pm).
טרמפיה
j-c health care ltd - guselkumab - תמיסה להזרקה - guselkumab 100 mg / 1 ml - guselkumab
אורנסיה 250 מג
bristol, myers squibb (israel) limited, israel - abatacept - אבקה להכנת תמיסה מרוכזת לעירוי - abatacept 250 mg - abatacept - abatacept - orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease modifying anti rheumatic drugs (dmards) including methotrexate (mtx) or a tnf-alpha inhibitor.a reduction in the progression of joint damage and improvement of physical function have been demonstrated during combination treatment with abatacept and methotrexate.polyarticular juvenile idiopathic arthritis:orencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (jia) in paediatric patients 6 years of age and older who have had an insufficient response to other dmards including at least one tnf inhibitor. orencia has not been studied in children under 6 years old.